Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: The epidemiological evidence
Standard
Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: The epidemiological evidence. / Koenig, Wolfgang; Khuseyinova, Natalie.
In: CARDIOVASC DRUG THER, Vol. 23, No. 1, 02.2009, p. 85-92.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: The epidemiological evidence
AU - Koenig, Wolfgang
AU - Khuseyinova, Natalie
PY - 2009/2
Y1 - 2009/2
N2 - INTRODUCTION: Among other lipid related biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and type II secretory phospholipase A(2) (sPLA(2)) represent emerging candidates for refined assessment of future cardiovascular disease (CVD) risk. Indeed, emerging evidence from more than prospective 15 studies conducted since 2000, clearly demonstrate the prognostic ability of increased Lp-PLA(2) concentrations or elevated activity for risk of future coronary heart disease (CHD) and stroke. Moreover, Lp-PLA(2) might have similar predictive power for both, incident CHD in initially healthy subjects, as well as for recurrent events in those with clinically manifest atherosclerosis.DISCUSSION: By contrast, to date, there are only few prospective studies that have investigated the relationship of sPLA(2) with future CVD risk. However, most of them show a positive association between increased mass or elevated activity and future atherosclerotic complications. Nonetheless, since inhibitors of Lp-PLA(2) and sPLA(2) have already been developed, these enzymes may be considered as novel therapeutic targets to treat residual risk in certain high risk patient groups.CONCLUSION: This review summarizes the epidemiologic evidence on the association between increased mass or elevated activity of these two phospholipases and risk of CVD.
AB - INTRODUCTION: Among other lipid related biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and type II secretory phospholipase A(2) (sPLA(2)) represent emerging candidates for refined assessment of future cardiovascular disease (CVD) risk. Indeed, emerging evidence from more than prospective 15 studies conducted since 2000, clearly demonstrate the prognostic ability of increased Lp-PLA(2) concentrations or elevated activity for risk of future coronary heart disease (CHD) and stroke. Moreover, Lp-PLA(2) might have similar predictive power for both, incident CHD in initially healthy subjects, as well as for recurrent events in those with clinically manifest atherosclerosis.DISCUSSION: By contrast, to date, there are only few prospective studies that have investigated the relationship of sPLA(2) with future CVD risk. However, most of them show a positive association between increased mass or elevated activity and future atherosclerotic complications. Nonetheless, since inhibitors of Lp-PLA(2) and sPLA(2) have already been developed, these enzymes may be considered as novel therapeutic targets to treat residual risk in certain high risk patient groups.CONCLUSION: This review summarizes the epidemiologic evidence on the association between increased mass or elevated activity of these two phospholipases and risk of CVD.
KW - 1-Alkyl-2-acetylglycerophosphocholine Esterase/antagonists & inhibitors
KW - Biomarkers
KW - Cardiovascular Diseases/diagnosis
KW - Clinical Trials as Topic
KW - Drug Delivery Systems
KW - Enzyme Inhibitors/pharmacology
KW - Humans
KW - Phospholipases A2, Secretory/antagonists & inhibitors
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Factors
U2 - 10.1007/s10557-008-6135-6
DO - 10.1007/s10557-008-6135-6
M3 - SCORING: Review article
C2 - 18949547
VL - 23
SP - 85
EP - 92
JO - CARDIOVASC DRUG THER
JF - CARDIOVASC DRUG THER
SN - 0920-3206
IS - 1
ER -